Caidya and Simbec-Orion Unite to Create Global Specialty CRO for End-to-End Drug Development
Caidya has announced a strategic combination with Simbec-Orion, marking a significant milestone in the clinical research industry by creating a global specialty contract research organization (CRO) designed to support biopharmaceutical companies throughout the entire drug development journey. The partnership aims to bridge the gap between early scientific discovery and large-scale global clinical execution, providing sponsors with a seamless path from first-in-human studies through late-stage clinical trials and regulatory approval.
The newly combined organization brings together complementary capabilities that strengthen clinical development services while preserving the responsiveness and accountability typically associated with specialist CROs. By integrating Caidya’s global operational platform with Simbec-Orion’s established expertise in early-phase research and European clinical development, the company is positioned to serve innovative biotechnology and pharmaceutical organizations developing complex therapies across multiple regions.
Expanding Global Clinical Development Capabilities
The merger creates a more comprehensive clinical development partner with operations spanning Europe, North America, Asia-Pacific, and China. This expanded geographic footprint enables sponsors to conduct multinational clinical programs with a single research partner capable of coordinating studies across major pharmaceutical markets.
As clinical trials increasingly become global in nature, pharmaceutical companies face growing challenges related to regulatory compliance, patient recruitment, operational consistency, and data management across multiple countries. The combined capabilities of Caidya and Simbec-Orion are intended to simplify these challenges by providing integrated project management and clinical expertise under one organization.
The strategic combination reflects the evolving needs of the global biopharmaceutical industry, where companies increasingly seek research partners capable of managing every phase of development while maintaining scientific continuity from laboratory discovery through commercialization.
Complementary Strengths Across the Development Lifecycle
One of the defining advantages of the combination is the complementary nature of each company’s expertise.
Simbec-Orion contributes extensive experience in early-phase clinical pharmacology, including first-in-human studies involving both healthy volunteers and patients. The organization also possesses deep expertise in oncology and rare disease research, supporting clinical development programs through Phase I, Phase II, and Phase III trials.
Caidya complements these strengths with an established global clinical operations platform, broad therapeutic experience, and infrastructure capable of executing complex international studies across diverse regulatory environments.
Together, these capabilities create a continuous clinical development pathway that reduces operational handoffs between multiple research organizations. Sponsors can now work with a single CRO from the earliest stages of drug development through pivotal registration studies, improving efficiency while maintaining institutional knowledge throughout the process.
Strong Presence Across Key Pharmaceutical Markets
The combined company significantly expands its international reach.
With established operations throughout Europe, the Americas, Asia-Pacific, and China, the organization is positioned to support multinational clinical programs involving diverse patient populations and regulatory agencies.
Europe remains one of the world’s most important regions for clinical research due to its highly developed healthcare systems, experienced investigators, and strong regulatory framework. Simbec-Orion’s longstanding European presence strengthens Caidya’s capabilities within this important market while simultaneously providing Simbec-Orion with broader access to North American and Asian clinical research opportunities.
This expanded network is expected to benefit biotechnology companies seeking efficient global development strategies without relying on multiple regional CRO partners.
Nearly Five Decades of Clinical Research Experience
Simbec-Orion brings almost fifty years of experience supporting innovative pharmaceutical and biotechnology companies.
Throughout its history, the organization has developed expertise in managing some of the industry’s most challenging clinical development programs, particularly within oncology, rare diseases, and clinical pharmacology.
Its reputation has been built on helping sponsors navigate increasingly complex regulatory requirements while maintaining high scientific standards and operational quality.
The company’s experience spans multiple therapeutic areas and includes support for numerous investigational products progressing from early clinical evaluation to regulatory submission.
Advanced Phase I Clinical Pharmacology Facility
Among Simbec-Orion’s most valuable assets is its 48-bed Phase I clinical pharmacology unit, recognized as one of Europe’s leading early-phase clinical research facilities.
The dedicated unit enables sponsors to conduct first-in-human studies under highly controlled conditions while supporting rapid transition into subsequent development stages.
Access to this specialized infrastructure enhances the combined organization’s ability to deliver integrated early-phase development services, particularly for biotechnology companies seeking efficient proof-of-concept studies.
Maintaining continuity between early clinical pharmacology and later-stage development reduces the need for transferring programs between different research organizations, preserving critical scientific knowledge while minimizing delays.
Supporting Complex Therapeutic Areas
The combined organization strengthens expertise across several high-growth therapeutic areas where clinical development often presents unique scientific and operational challenges.
Oncology remains one of the fastest-growing segments of pharmaceutical research, requiring sophisticated trial designs, biomarker integration, and coordination across specialized treatment centers.
Similarly, rare disease research often involves limited patient populations, international recruitment strategies, and close collaboration with regulatory authorities.
By combining therapeutic expertise with global operational capabilities, the new organization aims to help sponsors navigate these complex development environments more efficiently.
Leadership Highlights Strategic Vision
Barbara Lopez Kunz, Chief Executive Officer of Caidya, described the transaction as an important step toward creating a more complete development partner for pharmaceutical innovators.
She explained that combining Simbec-Orion’s European expertise and early-phase capabilities with Caidya’s international platform enables sponsors to receive continuous support from first-in-human research through regulatory registration. According to Kunz, the combined company is particularly well positioned to help clients overcome challenges where scientific innovation intersects with operational complexity and global clinical execution.
Her comments emphasize the company’s intention to preserve the personalized service model associated with specialist CROs while expanding its international capabilities.
Shared Culture Supports Integration
Fabrice Chartier, Chief Executive Officer of Simbec-Orion, highlighted the strong cultural alignment between the two organizations as a key factor supporting the strategic combination.
According to Chartier, both companies share a commitment to close collaboration, responsiveness, and scientific excellence, creating a solid foundation for future growth.
He noted that the combined organization brings together the flexibility and client focus of a specialist CRO with the geographic reach and infrastructure of a global development partner.
Chartier also emphasized that the expanded footprint provides Simbec-Orion with stronger access to the U.S. and Asian markets while simultaneously increasing Caidya’s European presence and enhancing its early-phase clinical pharmacology capabilities.
Meeting the Needs of Cross-Border Innovation
Dr. Lingshi Tan, Executive Chairman of Caidya’s Board, believes the transaction reflects broader trends reshaping global pharmaceutical innovation.
Drug development is increasingly becoming international, with therapies frequently originating in one region before progressing through multinational clinical programs involving research centers across the United States, Europe, and Asia.
Tan stated that integrating Simbec-Orion’s specialized expertise with Caidya’s global platform positions the company to support this growing flow of cross-border innovation while providing sponsors with consistent operational support throughout international development programs.
Investor Confidence in Future Growth
The transaction also received strong support from Simbec-Orion shareholder CBPE.
Anand Jain, Partner at CBPE and Chairman of Simbec-Orion, noted that the investment firm has supported substantial investments in talent, operational capabilities, and digital transformation since 2019.
He expressed confidence that combining Simbec-Orion with Caidya represents the next stage of growth for the business while creating additional value for employees, clients, and development partners.
Jain emphasized that maintaining a continuous relationship with a trusted research partner throughout drug development can improve efficiency while preserving scientific expertise from early human studies through regulatory submission.
Leadership Structure Following the Combination
Following completion of the transaction, the combined organization will continue operating under the leadership of Barbara Lopez Kunz as Chief Executive Officer.
Fabrice Chartier will remain responsible for leading Simbec-Orion’s operations within the integrated organization, helping ensure continuity for existing clients while supporting broader international expansion.
This leadership structure is intended to preserve the strengths of both companies while facilitating operational integration and long-term growth.
Building a More Complete CRO Platform
The strategic combination positions the new organization as a differentiated specialty CRO capable of delivering integrated services across the full clinical development spectrum.
By combining early scientific expertise, advanced clinical pharmacology infrastructure, therapeutic specialization, multinational operational capabilities, and broad geographic coverage, the company aims to offer biotechnology and pharmaceutical sponsors a single development partner capable of managing increasingly complex global clinical programs.
As the pharmaceutical industry continues to accelerate innovation in areas such as oncology, rare diseases, and precision medicine, demand for CROs capable of providing seamless end-to-end development support is expected to increase. The Caidya-Simbec-Orion combination represents a strategic response to these evolving market requirements, creating an organization focused on helping innovators bring life-changing therapies to patients worldwide with greater speed, continuity, and scientific excellence.
